Main Street Research’s Regeneron Pharmaceuticals REGN Stock Holding History

Main Street Research’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-27,610	Closed	-$15.5M	–	136
2020 Q3	$15.5M	Buy	27,610 +1,648	+6%	+$999K	1.97%	26
2020 Q2	$16.2M	Buy	25,962 +1,537	+6%	+$872K	2.54%	14
2020 Q1	$11.9M	Buy	+24,425	New	+$10.1M	2.92%	16
2017 Q4	–	Sell	-725	Closed	-$324K	–	112
2017 Q3	$324K	Sell	725 -200	-22%	-$95.2K	0.05%	89
2017 Q2	$454K	Buy	+925	New	+$405K	0.07%	85

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Main Street Research's REGN Position: Q4 2020 in Review

Main Street Research sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 27,610 shares — an estimated $15.5M sold.

Main Street Research first reported a position in REGN in Q2 2017 and held it in 5 quarters. The position peaked at $16.2M in Q2 2020. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

Main Street Research reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Main Street Research sold 27,610 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $15.5M.
Main Street Research first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 5 quarters.
Main Street Research's Regeneron Pharmaceuticals position peaked at $16.2M in Q2 2020.
903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Main Street Research's 13F filing for Q4 2020, filed 12 Feb 2021.